Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP)
CUSIP: 64136E102
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.00001 par value per share
- Shares outstanding
- 5,420,049
- Total 13F shares
- 177,963
- Share change
- +14,849
- Total reported value
- $1,263,538
- Price per share
- $7.10
- Number of holders
- 9
- Value change
- +$105,431
- Number of buys
- 3
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 64136E102?
CUSIP 64136E102 identifies NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 64136E102:
Top shareholders of NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,033,796
|
$5,365,401 | $0 | 31 Dec 2024 | |
| AdvisorShares Investments LLC |
13F
|
Company |
1.3%
|
69,659
|
$397,056 | — | 31 Mar 2025 | |
| Apeiron Investment Group Ltd. |
13D/G
|
— |
4.5%
|
72,618
|
$376,887 | $0 | 24 Jan 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
0.85%
|
45,806
|
$263,843 | — | 31 Mar 2025 | |
| Prosperity Wealth Management, Inc. |
13F
|
Company |
0.5%
|
27,200
|
$156,672 | — | 31 Mar 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
0.18%
|
10,027
|
$57,756 | — | 31 Mar 2025 | |
| Cyndeo Wealth Partners, LLC |
13F
|
Company |
0.18%
|
10,000
|
$57,600 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.01%
|
415
|
$2,389 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
7
|
$40 | — | 31 Mar 2025 |
Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.